Analysis of the correspondence of the lists of drugs for cancer patients' treatment included in the territorial programs of state guarantees to the list of vital and essential drugs

Author:

Zudin Alexander B.1ORCID,Linnik Sergey A.1ORCID,Alexandrova Oxana Yu.1ORCID

Affiliation:

1. N.A. Semashko National Research Institute of Public Health

Abstract

The aim of the study was to study the compliance of the list of drugs for the treatment of malignant neoplasms in the territorial state guarantee programs (TSGP) with the list of vital and essential drugs (VED) in the constituent entities of the Russian Federation and the practice of purchasing drugs at the expense of regional preferential provision (RPP) funds. Material and methods. The analyzed territorial programs of state guarantees were compared with the list of drugs for RPP for the patients with malignant neoplasms with the VED. An assessment of medication procurement in 2019 and 2020 was carried out and compared with the current list of RLO in all constituent entities of the Russian Federation. Results. Only 14% of the Russian Federation regions in 2019 and 20% in 2020 met the territorial state program of guarantees requirement. The average number of medications included in the territorial state program of guarantees was 73 INNs in 2019 and 100 INNs in 2020. The number of regions with a complete list of drugs accounted for 7% to 33% in the corresponding Federal Districts. In 2020 the number of regions with a complete list of medications in a territorial program of state guarantees did not change. Discussion. Reduction of medications from the VED purchased at the expense of RPP reduces the number of possible treatment regimens, and limits oncologists’ ability to provide care on an outpatient basis. Conclusion. Most Russian Federation regions violate the requirements of the territorial program of state guarantees do not harmonize the list of medications in the Program with EDL. The practice of purchasing medications from the territorial program of state guarantees indicates the absence of finance mechanisms for providing medications to patients at the outpatient stage of treatment.

Publisher

Federal Scientific Center for Hygiene F.F.Erisman

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference8 articles.

1. Tel’nova E.A., Zagoruychenko A.A. About state regulation in the Russian pharmaceutical market and problems of drug supply. Sovremennaya organizatsiya lekarstvennogo obespecheniya. 2020; 7(3): 11–20. https://doi.org/10.30809/solo.3.2020.2 (in Russian)

2. Dzanaeva A.V., Omel’yanovskiy V.V., Kagermazova S.A. Innovative drugs in the system of preferential drug supply. Meditsinskie tekhnologii. Otsenka i vybor. 2015; (3): 41–6. (in Russian)

3. Spasennikov B.A., Bezmel’nitsyna L.Yu. The problems of pre-ferential medicinal provision. Aktual’nye problemy meditsiny i biologii. 2018; (3): 58–62. https://doi.org/10.24411/2587-4926-2018-10041 (in Russian)

4. Khabriev R.U., Sukhodolov A.P., Spasennikov B.A., Bezmel’nitsyna L.Yu., Meshkov D.O. The decision-making system in the program of subsidized pharmaceutical provision. Izvestiya Baykal’skogo gosudarstvennogo universiteta. 2018; 28(1): 6–11. https://doi.org/10.17150/2500-2759.2018.28(1).6-11 (in Russian)

5. Petrukhina I.K., Egorova A.V., Loginova L.V., Bubnova A.A. The analysis of features of realization of regional programs of preferential provision of medicines in some territorial subjects of the Russian Federation depending on categories of diseases. Sovremennaya organizatsiya lekarstvennogo obespecheniya. 2019; (2): 63–4. (in Russian)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3